Biotechnology Fund Investor Fund Manager Performance Evaluation

RYOIX Fund  USD 78.05  10.66  15.82%   
The fund shows a Beta (market volatility) of 0.19, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Biotechnology Fund's returns are expected to increase less than the market. However, during the bear market, the loss of holding Biotechnology Fund is expected to be smaller as well.

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Biotechnology Fund Investor has generated negative risk-adjusted returns adding no value to fund investors. In spite of fairly strong forward indicators, Biotechnology Fund is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.
...more
Expense Ratio Date19th of August 2022
Expense Ratio1.4000
  

Biotechnology Fund Relative Risk vs. Return Landscape

If you would invest  8,126  in Biotechnology Fund Investor on September 18, 2024 and sell it today you would lose (321.00) from holding Biotechnology Fund Investor or give up 3.95% of portfolio value over 90 days. Biotechnology Fund Investor is currently producing negative expected returns and takes up 2.8731% volatility of returns over 90 trading days. Put another way, 25% of traded mutual funds are less volatile than Biotechnology, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days.
  Expected Return   
       Risk  
Assuming the 90 days horizon Biotechnology Fund is expected to under-perform the market. In addition to that, the company is 3.91 times more volatile than its market benchmark. It trades about -0.01 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.12 per unit of volatility.

Biotechnology Fund Current Valuation

Fairly Valued
Today
78.05
Please note that Biotechnology Fund's price fluctuation is very steady at this time. At this time, the entity appears to be fairly valued. Biotechnology Fund shows a prevailing Real Value of $77.21 per share. The current price of the fund is $78.05. We determine the value of Biotechnology Fund from analyzing fund fundamentals and technical indicators as well as its Probability Of Bankruptcy. In general, we favor acquiring undervalued mutual funds and dropping overvalued mutual funds since, at some point, mutual fund prices and their ongoing real values will blend.
Since Biotechnology Fund is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Biotechnology Mutual Fund. However, Biotechnology Fund's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  78.05 Real  77.21 Hype  78.05
The intrinsic value of Biotechnology Fund's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Biotechnology Fund's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
77.21
Real Value
80.08
Upside
Estimating the potential upside or downside of Biotechnology Fund Investor helps investors to forecast how Biotechnology mutual fund's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Biotechnology Fund more accurately as focusing exclusively on Biotechnology Fund's fundamentals will not take into account other important factors:
Hype
Prediction
LowEstimatedHigh
75.1878.0580.92
Details

Biotechnology Fund Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Biotechnology Fund's investment risk. Standard deviation is the most common way to measure market volatility of mutual funds, such as Biotechnology Fund Investor, and traders can use it to determine the average amount a Biotechnology Fund's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = -0.0082

Best PortfolioBest Equity
Good Returns
Average Returns
Small Returns
CashSmall RiskAverage RiskHigh RiskHuge Risk
Negative ReturnsRYOIX

Estimated Market Risk

 2.87
  actual daily
25
75% of assets are more volatile

Expected Return

 -0.02
  actual daily
0
Most of other assets have higher returns

Risk-Adjusted Return

 -0.01
  actual daily
0
Most of other assets perform better
Based on monthly moving average Biotechnology Fund is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Biotechnology Fund by adding Biotechnology Fund to a well-diversified portfolio.

Biotechnology Fund Fundamentals Growth

Biotechnology Mutual Fund prices reflect investors' perceptions of the future prospects and financial health of Biotechnology Fund, and Biotechnology Fund fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biotechnology Mutual Fund performance.

About Biotechnology Fund Performance

Evaluating Biotechnology Fund's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Biotechnology Fund has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Biotechnology Fund has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Under normal circumstances, the fund invests substantially all of its net assets in equity securities of Biotechnology Companies that are traded in the United States and in derivatives, which primarily consist of futures contracts and options on securities, futures contracts, and stock indices. It may invest to a significant extent in the securities of Biotechnology Companies that have small to mid-sized capitalizations. The fund is non-diversified.

Things to note about Biotechnology Fund performance evaluation

Checking the ongoing alerts about Biotechnology Fund for important developments is a great way to find new opportunities for your next move. Mutual Fund alerts and notifications screener for Biotechnology Fund help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Biotechnology Fund generated a negative expected return over the last 90 days
The fund generated three year return of -1.0%
Biotechnology Fund maintains 99.51% of its assets in stocks
Evaluating Biotechnology Fund's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Biotechnology Fund's mutual fund performance include:
  • Analyzing Biotechnology Fund's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biotechnology Fund's stock is overvalued or undervalued compared to its peers.
  • Examining Biotechnology Fund's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Biotechnology Fund's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biotechnology Fund's management team can help you assess the Mutual Fund's leadership.
  • Pay attention to analyst opinions and ratings of Biotechnology Fund's mutual fund. These opinions can provide insight into Biotechnology Fund's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Biotechnology Fund's mutual fund performance is not an exact science, and many factors can impact Biotechnology Fund's mutual fund market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Other Information on Investing in Biotechnology Mutual Fund

Biotechnology Fund financial ratios help investors to determine whether Biotechnology Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biotechnology with respect to the benefits of owning Biotechnology Fund security.
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges